Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Reata Pharmaceuticals

Nasdaq:RETA
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RETA
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Reata Pharmaceuticals has significant price volatility in the past 3 months.
RETA Share Price and Events
7 Day Returns
1.4%
NasdaqGM:RETA
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
52%
NasdaqGM:RETA
-2%
US Pharmaceuticals
-10%
US Market
RETA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Reata Pharmaceuticals (RETA) 1.4% -21.3% -35.1% 52% 534.8% -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • RETA outperformed the Pharmaceuticals industry which returned -2% over the past year.
  • RETA outperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
RETA
Industry
5yr Volatility vs Market

RETA Value

 Is Reata Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Reata Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $134.65.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Reata Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Reata Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:RETA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-9.54
NasdaqGM:RETA Share Price ** NasdaqGM (2020-04-07) in USD $134.65
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Reata Pharmaceuticals.

NasdaqGM:RETA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RETA Share Price ÷ EPS (both in USD)

= 134.65 ÷ -9.54

-14.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Reata Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Reata Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Reata Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:RETA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
54.2%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Reata Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Reata Pharmaceuticals's assets?
Raw Data
NasdaqGM:RETA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $7.74
NasdaqGM:RETA Share Price * NasdaqGM (2020-04-07) in USD $134.65
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:RETA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RETA Share Price ÷ Book Value per Share (both in USD)

= 134.65 ÷ 7.74

17.4x

* Primary Listing of Reata Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Reata Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Reata Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Reata Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RETA Future Performance

 How is Reata Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Reata Pharmaceuticals expected to grow at an attractive rate?
  • Reata Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Reata Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Reata Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:RETA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:RETA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 54.2%
NasdaqGM:RETA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 62.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:RETA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:RETA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 2,018 619 987 3
2023-12-31 1,049 243 333 3
2022-12-31 401 -29 -130 3
2021-12-31 63 -353 -326 6
2020-12-31 5 -249 -294 5
2020-04-08
NasdaqGM:RETA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 27 -251 -290
2019-09-30 31 -139 -129
2019-06-30 28 -96 -120
2019-03-31 28 -88 -114
2018-12-31 54 -84 -81
2018-09-30 55 -71 -72
2018-06-30 62 -93 -53
2018-03-31 67 -85 -36
2017-12-31 48 -83 -48
2017-09-30 50 -70 -35
2017-06-30 50 -47 -24
2017-03-31 50 -42 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Reata Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Reata Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:RETA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Reata Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RETA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 23.81 32.18 12.41 3.00
2023-12-31 8.13 16.18 3.62 3.00
2022-12-31 -3.57 -1.22 -5.13 3.00
2021-12-31 -9.14 -7.25 -11.88 6.00
2020-12-31 -8.39 -5.57 -10.81 7.00
2020-04-08
NasdaqGM:RETA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -9.54
2019-09-30 -4.30
2019-06-30 -4.05
2019-03-31 -3.98
2018-12-31 -2.91
2018-09-30 -2.67
2018-06-30 -2.06
2018-03-31 -1.47
2017-12-31 -1.99
2017-09-30 -1.53
2017-06-30 -1.06
2017-03-31 -0.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Reata Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Reata Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Reata Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RETA Past Performance

  How has Reata Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Reata Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Reata Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Reata Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Reata Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Reata Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Reata Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RETA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 26.52 -290.17 58.30
2019-09-30 31.06 -128.81 43.97
2019-06-30 28.20 -119.95 37.18
2019-03-31 27.91 -113.78 36.16
2018-12-31 53.59 -80.55 32.75
2018-09-30 54.65 -71.64 30.75
2018-06-30 61.70 -53.11 29.41
2018-03-31 66.54 -36.49 24.72
2017-12-31 48.06 -47.67 23.26
2017-09-30 50.09 -35.13 22.13
2017-06-30 50.09 -23.72 20.02
2017-03-31 50.09 -13.07 18.57
2016-12-31 49.73 -6.23 16.60
2016-09-30 49.73 -3.84 16.27
2016-06-30 49.73 -2.31 15.21
2016-03-31 49.73 -3.07 14.05
2015-12-31 50.30 -1.45 13.69
2015-09-30 50.29 0.22 12.67 -24.87
2015-06-30 50.66 -0.22 12.47
2015-03-31 51.29 1.76 11.73
2014-12-31 51.37 0.69 11.51
2013-12-31 51.03 -35.57 11.98 40.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Reata Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Reata Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Reata Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Reata Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Reata Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RETA Health

 How is Reata Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Reata Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Reata Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Reata Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Reata Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Reata Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:RETA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 256.86 155.02 664.32
2019-09-30 -67.42 80.24 240.15
2019-06-30 -33.47 79.90 280.45
2019-03-31 -4.61 79.56 313.06
2018-12-31 15.16 79.22 337.79
2018-09-30 37.55 78.88 375.19
2018-06-30 -167.87 78.59 138.68
2018-03-31 -142.70 19.67 105.94
2017-12-31 -146.97 19.61 129.78
2017-09-30 -132.42 19.83 154.60
2017-06-30 -230.31 19.79 65.18
2017-03-31 -220.31 19.75 82.68
2016-12-31 -215.05 0.00 84.73
2016-09-30 -212.29 0.00 95.66
2016-06-30 -212.14 0.00 92.37
2016-03-31 -273.01 0.00 41.85
2015-12-31 -273.16 0.00 42.01
2015-09-30 -272.57 0.00 55.05
2015-06-30 -273.64 0.00 66.27
2015-03-31 -274.25 0.00 87.76
2014-12-31 -274.25 0.00 87.76
2013-12-31 -277.06 0.00 176.53
  • Reata Pharmaceuticals's level of debt (60.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if Reata Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Reata Pharmaceuticals has sufficient cash runway for 2.6 years based on current free cash flow.
  • Reata Pharmaceuticals has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 23.8% each year.
X
Financial health checks
We assess Reata Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Reata Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RETA Dividends

 What is Reata Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Reata Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Reata Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Reata Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Reata Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:RETA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:RETA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Reata Pharmaceuticals has not reported any payouts.
  • Unable to verify if Reata Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Reata Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Reata Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Reata Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Reata Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Reata Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Reata Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RETA Management

 What is the CEO of Reata Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Huff
COMPENSATION $934,500
AGE 65
TENURE AS CEO 18.3 years
CEO Bio

Mr. J. Warren Huff has been the Chief Executive Officer and President of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) since founding in 2002 and has been its Chairman since 2002. Mr. Huff is Venture Partner of StarTech Medical Ventures. Prior to founding Reata, Mr. Huff served as Chief Executive Officer in a number of biotech and information technology start-up enterprises. From 1998 to 2001, he served as President and Chief Executive Officer of OpenPages, Inc. From 1997 to 1998, Mr. Huff founded InLight Inc. and served as its President and Chief Executive Officer. From 1992 to 1996, he served as President and Chief Executive Officer of Ergo Science Corporation. Mr. Huff served as Chief Executive Officer in a number of health care and information technology start-up enterprises including Light Biology Inc., OpenPages, Inc. and InLight Corporation. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was Partner and Chairman of the Corporate Securities Practice. He served as Director of Ergo Science Corporation from February 2001 to October 24, 2005. Mr. Huff received his J.D. from the Southern Methodist University School of Law and graduated magna cum laude with a BBA from University of Texas at Austin.

CEO Compensation
  • J.'s compensation has been consistent with company performance over the past year, both up more than 20%.
  • J.'s remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Reata Pharmaceuticals management team in years:

1.4
Average Tenure
49
Average Age
  • The average tenure for the Reata Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

J. Huff

TITLE
Chairman
COMPENSATION
$935K
AGE
65
TENURE
18.3 yrs

Colin Meyer

TITLE
Chief Medical Officer & Executive VP of Product Development
COMPENSATION
$626K
AGE
40

Manmeet Soni

TITLE
CFO & Executive VP
AGE
41
TENURE
0.7 yrs

Jason Wilson

TITLE
Executive Vice President of Operations
COMPENSATION
$428K
AGE
49
TENURE
0.7 yrs

Elaine Castellanos

TITLE
VP & Chief Accounting Officer

Mike Wortley

TITLE
Executive VP & Chief Legal Officer
AGE
71
TENURE
5 yrs

Vinny Jindal

TITLE
VP of Corporate Communications & Strategy

Claudia Bujold

TITLE
Vice President of Marketing
TENURE
1.8 yrs

Steve Harman

TITLE
VP & Chief Human Resources Officer
TENURE
1 yrs

Joel Proksch

TITLE
Chief Development Officer & Senior VP of Regulatory
Board of Directors Tenure

Average tenure and age of the Reata Pharmaceuticals board of directors in years:

15.3
Average Tenure
57
Average Age
  • The average tenure for the Reata Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

J. Huff

TITLE
Chairman
COMPENSATION
$935K
AGE
65
TENURE
18.3 yrs

Jack Nielsen

TITLE
Lead Independent Director
COMPENSATION
$299K
AGE
55

Bill McClellan

TITLE
Independent Director
COMPENSATION
$293K
AGE
59
TENURE
3.1 yrs

Richard McGaughy

TITLE
Independent Director
COMPENSATION
$261K
AGE
47
TENURE
15.3 yrs

Jim Bass

TITLE
Independent Director
COMPENSATION
$268K
AGE
60
TENURE
15.8 yrs

William Rose

TITLE
Independent Director
COMPENSATION
$264K
AGE
51
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
20. Nov 19 Sell Charles Gale Individual 08. Nov 19 19. Nov 19 -3,000 $210.00 $-622,009
18. Nov 19 Buy CPMG, Inc. Company 18. Nov 19 18. Nov 19 40,218 $183.00 $7,359,894
30. Sep 19 Sell J. Huff Individual 23. Sep 19 27. Sep 19 -82,500 $86.61 $-5,456,115
X
Management checks
We assess Reata Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Reata Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RETA News

Simply Wall St News

Are Insiders Selling Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock?

So we'll take a look at whether insiders have been buying or selling shares in Reata Pharmaceuticals, Inc. … NasdaqGM:RETA Recent Insider Trading, September 4th 2019 Does Reata Pharmaceuticals Boast High Insider Ownership? … It's great to see high levels of insider ownership, but looking back at the last year, we don't gain confidence from the Reata Pharmaceuticals insiders selling.

Simply Wall St -

Loss-Making Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Expected To Breakeven

In this article, I will touch on the expectations for RETA’s growth and when analysts expect the company to become profitable. … See our latest analysis for Reata Pharmaceuticals According to the 6 industry analysts covering RETA, the consensus is breakeven is near. … Next Steps: There are too many aspects of RETA to cover in one brief article, but the key fundamentals for the company can all be found in one place – RETA’s company page on Simply Wall St.

Simply Wall St -

Reata Pharmaceuticals's (NASDAQ:RETA) Wonderful 454% Share Price Increase Shows How Capitalism Can Build Wealth

Check out our latest analysis for Reata Pharmaceuticals Because Reata Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … This is in stark contrast to the strong share price growth of 77%, compound, per year. … There can be no doubt this kind of decoupling of revenue growth and share price growth is unusual to see in loss making companies.

Simply Wall St -

Reata Pharmaceuticals (NASDAQ:RETA) Is Using Debt In A Risky Way

NasdaqGM:RETA Historical Debt, July 3rd 2019 How Healthy Is Reata Pharmaceuticals's Balance Sheet? … This state of affairs indicates that Reata Pharmaceuticals's balance sheet looks quite solid, as its total liabilities are just about equal to its liquid assets. … Reata Pharmaceuticals boasts net cash, so it's fair to say it does not have a heavy debt load!

Simply Wall St -

How Much Are Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Insiders Taking Off The Table?

So we'll take a look at whether insiders have been buying or selling shares in Reata Pharmaceuticals, Inc. … Insider Ownership of Reata Pharmaceuticals Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. … An insider sold Reata Pharmaceuticals shares recently, but they didn't buy any.

Simply Wall St -

Do Insiders Own Lots Of Shares In Reata Pharmaceuticals, Inc. (NASDAQ:RETA)?

A look at the shareholders of Reata Pharmaceuticals, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Imagine Holding Reata Pharmaceuticals (NASDAQ:RETA) Shares While The Price Zoomed 310% Higher

(NASDAQ:RETA) share price rocketed moonwards 310% in just one year. … Because Reata Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … So it's truly surprising that the share price rocketed 310% in a single year.

Simply Wall St -

When Can We Expect A Profit From Reata Pharmaceuticals, Inc. (NASDAQ:RETA)?

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. … The company’s loss has recently broadened since it announced a -US$47.7m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$71.6m, moving it further away from breakeven? … See our latest analysis for Reata Pharmaceuticals

Simply Wall St -

Have Insiders Been Buying Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Reata Pharmaceuticals, Inc. … Reata Pharmaceuticals Insider Transactions Over The Last Year. … We generally consider it a positive if insiders have been buying on market, even if the share price has increased a bit since then

Simply Wall St -

Market Sentiment Around Loss-Making Reata Pharmaceuticals Inc (NASDAQ:RETA)

Reata Pharmaceuticals Inc's (NASDAQ:RETA):. … The US$1.8b market-cap posted a loss in its most recent financial year of -US$47.7m and a latest trailing-twelve-month loss of -US$71.6m leading to an even wider gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for RETA, its year of breakeven and its implied growth rate

Simply Wall St -

RETA Company Info

Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich’s ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.

Details
Name: Reata Pharmaceuticals, Inc.
RETA
Exchange: NasdaqGM
Founded: 2002
$4,474,313,530
33,229,213
Website: http://www.reatapharma.com
Address: Reata Pharmaceuticals, Inc.
5320 Legacy Drive,
Plano,
Texas, 75024,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RETA Class A Common Stock Nasdaq Global Market US USD 26. May 2016
DB 2R3 Class A Common Stock Deutsche Boerse AG DE EUR 26. May 2016
Number of employees
Current staff
Staff numbers
220
Reata Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 09:22
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/19
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.